

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BIONEBRASKA, INC.	01/29/2003
RECEIVING PARTY DATA	
Name:	AMYLIN PHARMACEUTICALS, INC.
Street Address:	9360 Towne Centre Drive
Internal Address:	Intellectual Property Group
City:	San Diego
State/Country:	CALIFORNIA
Postal Code:	92121
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	12822165
CORRESPONDENCE DATA	
Fax Number:	(858)552-1936
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	858 552 2200
Email:	patents@amylin.com
Correspondent Name:	AMYLIN PHARMACEUTICALS, INC.
Address Line 1:	9360 Towne Centre Drive
Address Line 2:	Intellectual Property Group
Address Line 4:	San Diego, CALIFORNIA 92121
ATTORNEY DOCKET NUMBER:	0212US-DIV3
NAME OF SUBMITTER:	Renee Zavala
Total Attachments: 2 source=Assignmt-Bionebraska-Amylin#page1.tif source=Assignmt-Bionebraska-Amylin#page2.tif	

CH \$40.00 12822165

501273663

PATENT
REEL: 024894 FRAME: 0112

**ASSIGNMENT OF PATENTS, PENDING APPLICATIONS AND FOREIGN
EQUIVALENTS**

In consideration of One Dollar and other good and valuable considerations, the receipt and sufficiency whereof are hereby acknowledged, the undersigned **BioNebraska, Inc.**, also known as **Restoragen, Inc.**, a Delaware corporation, having an address of 5701 South 34th Street, Suite 203, Lincoln, Nebraska 68516, hereby assigns to **Amylin Pharmaceuticals, Inc.**, a Delaware corporation, having an address of 9373 Towne Centre Drive, San Diego, California 92121, its successors and assigns the entire right, title and interest in the invention or improvements of the undersigned disclosed in the following applications for Letters Patent of the United States:

<u>Serial No.</u>	<u>Filed</u>	<u>Title</u>
60/205,239	5/19/2000	Treatment Of Acute Coronary Syndrome With GIP-1
09/859,804	5/18/2001	Treatment Of Acute Coronary Syndrome With GIP-1
10/322,839	12/18/2002	Treatment Of Acute Coronary Syndrome With GIP-1

and in said applications and any and all other priority or related patents or applications for patents worldwide, which the undersigned has filed or may file, either solely or jointly with others, on said invention or improvements, and in any and all Letters Patent applications, and in any reissue or extension thereof, and in any and all foreign equivalents thereof.

The undersigned hereby authorizes and requests the Commissioner of Patents to issue said United States Letters Patent to said **AMYLIN PHARMACEUTICALS, INC.**

For said considerations the undersigned hereby agrees, upon the request, and at the expense of said Assignee, its successors and assigns, to execute any and all divisional, continuation and substitute applications for said invention or improvements, and any necessary oath or affidavit relating thereto, and any application for the reissue or extension of any Letters Patent that may be granted upon said application, and for the said considerations the undersigned further agrees upon the request of said Assignee, its successors or assigns, in the event of any application or Letters Patent assigned herein becoming involved in interference, to cooperate to

